Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

Exclusion Criteria

• •Acute ST-segment elevation myocardial infarction within 1 week.
• •Left main coronary artery disease, branch vessel diameter≥2.0mm, three-vessel coronary artery disease and bridge vessel disease; visible thrombus in the target vessel.
• •Severe distortion, severe calcification that cannot be successfully predilated, and other lesions that are not suitable for stent delivery and deployment.
• •Intra-stent restenosis.
• •Severe heart failure (NYHA≥III or left ventricular ejection fraction\<35%).
• •Severe renal insufficiency, eGFR\<30ml/min/1.73m2 or serum creatinine\>2.5mg/dL (221μmol/L).
• •Patients with bleeding tendency, active gastrointestinal ulcer, history of cerebral hemorrhage or subarachnoid hemorrhage, history of stroke within half a year, fundus hemorrhage affecting vision, antiplatelet agents and anticoagulant treatment contraindications who cannot receive antithrombotic therapy.
• •Patients requiring long-term oral anticoagulants during the study period.
• •Patients who are pregnant, breastfeeding, or planning to become pregnant during the study period.
• •Patients with malignancies, organ transplants, or drug addiction that can seriously affect study compliance.
• •Patients with contraindications to aspirin, clopidogrel or ticagrelor.
• •Known allergy to aspirin, clopidogrel, ticagrelor, heparin, contrast agent, polylactic acid polymer and rapamycin.
• •Thrombosis occurred during previous clopidogrel treatment.
• •Life expectancy is less than 36 months.
• •Participated in clinical trials of other drugs or medical devices before enrollment and failed to meet the time limit of the primary end point.
• •Patients who will have elective surgery within a year and need to discontinue aspirin, clopidogrel or ticagrelor.
• •Subjects are deemed unsuitable for enrollment by investigators.